FDA authorizes Ito Invivyd’s pemivibart (Pemgarda), insights on Sofosbuvir levels in pregnant women, the effectiveness of fidaxomicin vs vancomycin for CDI treatment, and more this week from Contagion.
Investigational, Non-Antibiotic Begins Phase 2 Trial for Recurrent C difficile
C difficile, Antimicrobials, and the Patients Most Affected
Top 5 Infectious Disease News Stories Week Of October 18-25
A Clinician’s Perspective on Rebyota for Recurrent C Diff Treatment
Real World Study of Recurrent Clostridioides difficile Therapy Demonstrates Efficacy, Safety
New Insights into Clostridioides difficile Infection and Vaccine Development